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Abstract
Background: The clinico-surgical implication and successful management of a rare case of factor
five (V) deficiency with portal hypertension and hypersplenism due to idiopathic extra-hepatic
portal venous obstruction is presented.
Case presentation: A 16-year old boy had gastro-esophageal variceal bleeding, splenomegaly and
hypersplenism. During preoperative workup prolonged prothrombin time and activated partial
thromboplastin time were detected, which on further evaluation turned out to be due to factor V
deficiency. Proximal lieno-renal shunt and splenectomy were successfully performed with
transfusion of fresh frozen plasma during and after the surgical procedure. At surgery there was no
excessive bleeding. The perioperative course was uneventful and the patient is doing well on follow
up.
Conclusion: Surgical portal decompressive procedures can be safely undertaken in clotting factor
deficient patients with portal hypertension if meticulous surgical hemostasis is achieved at
operation and the deficient factor is adequately replaced in the perioperative period.
Background
Congenital deficiency of factor V (parahemophilia) is a
rare inherited disorder of coagulation which appears to
follow an autosomal recessive or partially dominant pat-
tern [1-4]. Although the clinical features are rather mild
compared with hemophilia, any surgical procedure
undertaken without replacement therapy is uniformly
complicated by excessive hemorrhage [1,2,5]. As factor V
concentrate is not available, fresh frozen plasma (FFP) is
the only available source of factor V at the present time.
We report a boy with extra-hepatic portal venous obstruc-
tion (EHPVO), portal hypertension and upper gastroin-
testinal (UGI) hemorrhage who also had factor V
deficiency. Although many congenital anomalies such as
cleft palate, mental retardation, short stature, syndactyly,
atrial septal defect, ventricular septal defect, coarctation of
aorta, duplication of the genitourinary collecting system
have been associated with congenital deficiency of factor
V [1-4], the simultaneous occurrence of factor V deficiency
with EHPVO has not been described till date. EHPVO is a
relatively common cause of portal hypertension in India,
especially in the younger age group [6,7]. Many causes,
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such as congenital, umbilical sepsis, recurrent childhood
diarrhoea, dehydration, intra-abdominal infection, mal-
nutrition and neonatal exchange transfusion have been
postulated [6,8]. The aetiology of EHPVO still remains
unclear and in most it is labelled idiopathic.
Case presentation
A 16-year old boy was admitted to the Department of Gas-
trointestinal Surgery, All India Institute of Medical Sci-
ences (AIIMS), for the management of recurrent episodes
of UGI bleeding. He had the first episode of hematemesis
and melena at the age of 11 years. He was managed else-
where with 3 units of blood transfusion and endoscopic
sclerotherapy for esophageal varices. He had his esopha-
geal varices obliterated with 10 sessions of endoscopic
sclerotherapy. He had an episode of recurrent UGI bleed-
ing 9 months before presentation that was associated with
hemodynamic instability, for which he received 4 units of
blood transfusion and was subsequently referred to our
centre. Additionally, he complained of a progressively
growing lump in the left upper abdomen since the age of
3 years. He never had jaundice, ascites or encephalopathy.
There was no history of any gum bleed, epistaxis, ecchy-
mosis or prolonged bleeding from minor cuts. His general
physical examination was normal; abdominal examina-
tion revealed a 6 cm non-tender smooth splenomegaly
and a normal liver span. UGI endoscopy at AIIMS
revealed 3 columns of grade II esophageal varices and gas-
tric fundal varices. Duplex ultrasound scan of the abdo-
men showed a normal liver, splenomegaly and
obliterated portal vein with multiple collaterals (portal
cavernoma) in the hilum of the liver. Splenic vein calibre
was 12 mm. Although his hemoglobin was normal (13
gm/dl) the hemogram revealed features of hypersplenism
(low total leukocyte count: 2300/mm3 and low platelets:
70,000/mm3). Liver function tests, other than a pro-
longed prothrombin time (PT), were within normal limits
(viz., serum bilirubin: 0.7 mg/dl, serum alkaline phos-
phatase: 190 U/dl, serum aspartate transaminase: 32 U/dl,
serum alanine transaminase: 28 U/dl). PT, activated par-
tial thromboplastin time (APTT), and thromboelastogram
(TEG) were significantly deranged (Table 1). Assay for
clotting factors revealed factor V deficiency (activity less
than 20% of normal). Other clotting factor concentra-
tions were normal and the screening for factor inhibitors
was negative.
The possible problems during surgery with regard to
excessive bleeding were explained to the parents and an
informed written consent was obtained. A clinical haema-
tologist saw the patient and a plan for pre and peri-opera-
tive FFP infusions with coagulation monitoring was
decided upon. The patient was transfused 1500 ml of FFP
the day before operation. Following transfusion the PT,
APTT and TEG significantly improved (Table 1), although
they did not normalize. He was transfused 900 ml of FFP
over 3 hours just before the start of the operation. He
underwent splenectomy and proximal lieno-renal shunt
(PLRS) through a left thoraco-abdominal incision (8th
intercostal space) using a standardized surgical technique
described by us previously [7]. The intra-operative blood
loss was 1000 ml. During the operation he received two
units of packed cells and 750 ml of FFP. The operative
time was 4 hours and the patient remained hemodynam-
ically stable throughout the procedure. Postoperatively he
received 600 ml of FFP every 12 hours for the first 48
hours followed by 450 ml of FFP every 12 hours for the
next 48 hours. There was no bleeding from the drain sites
and the wounds healed well without haematoma forma-
tion. Abdominal drain and chest tube were removed on
3rd and 8th postoperative days, respectively. Patient had
high spiking fever ranging between 39°C–40°C in the ini-
tial postoperative period. Although the patient was ini-
tially started on i.v. amoxicillin with clavulinic acid and
amikacin as per our protocol, antibiotics were changed to
teicoplanin and piperacillin-tazobactam on the 3rd post-
operative day. He became afebrile on the 6th postoperative
day and intravenous antibiotics were continued till 10th
postoperative day. Cultures from blood, urine and drain
fluids were repeatedly sterile. An ultrasound evaluation
did not reveal any subphrenic or intra-abdominal collec-
tion. He was discharged on the 12th postoperative day.
Following discharge, at 4 months follow-up, the patient
has had no recurrence of variceal bleeding and no evi-
dence of hypersplenism (hemoglobin- 11 gm/dl, total
leukocyte count- 6600/mm3, platelets- 325,000/mm33).
Table 1: Results of laboratory investigations in the patient with 
factor V deficiency and EHPVO
Coagulation parameters before transfusion of fresh frozen plasma
Prothrombin time 24" (12")
APTT 54.8" (30")
Pre-transfusion Thromboelastographic parameters
Reaction time (R) 24" (19–28")
Coagulation time (K) 23.5" (8–13")
Maximum Amplitude (MA) 29.5 mm (48–60 mm)
Alpha Angle 22.5 degrees (29–43 degrees)
TEG index -3.4 (-2 to +2)
Coagulation parameters after transfusion of fresh frozen plasma
Prothrombin time 15.5" (12")
APTT 33.7" (30")
Post-transfusion Thromboelastographic parameters
Reaction time (R) 25" (19–28")
Coagulation time (K) 19" (8–13")
Maximum Amplitude (MA) 36 mm (48–60 mm)
Alpha Angle 26.5 degrees (29–43 degrees)
TEG index -2.6 (-2 to +2)
APTT, activated partial thromboplastin time; EHPVO, extra-hepatic 
portal venous obstruction; TEG, thromboelastogram; figures in 
parentheses indicate control values.BMC Surgery 2006, 6:7 http://www.biomedcentral.com/1471-2482/6/7
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A Doppler ultrasound study showed a patent lieno-renal
shunt.
Discussion
Factor V (labile factor or proaccelerin) is a large single
chain glycoprotein (2196 amino acids) and the gene for
factor V is located on chromosome 1 q21-q25. The aver-
age plasma concentration of factor V is 6.6 µg/ml (20
nmol/L). Platelets contain approximately 18–25% of the
factor V in whole blood, within ά granules. Liver appears
to be the primary site of factor V biosynthesis. Procofactor
V does not bind factor Xa and is essentially completely
inactive. The primary catalyst of factor V activation in-vivo
is ά-thrombin. Activation of procofactor V yields the func-
tional form of factor Va which acts as a cofactor for the ser-
ine protease factor Xa in the prothrombinase complex and
leads to a rate enhancement of almost 300,000 fold in the
process of factor Xa activation of prothrombin [4]. Factor
V is an extremely labile protein and is rapidly degraded in
stored blood or plasma. As no factor V concentrate or
recombinant factor V is available, treatment consists of
fresh frozen plasma (FFP). The half-life of factor V is prob-
ably about 12 to 15 hours although a range from 4.5 to 36
hours has been described [1-5,9]. More rapid disappear-
ance is expected during surgery due to bleeding. In this
context it is pertinent to state that infusions of solvent/
detergent (S/D) plasma have been shown to have signifi-
cant reductions in the activity of factors V, VIII and protein
S. Hence its use is not considered appropriate for patients
with factor V deficiency undergoing surgery, even though
the risks of viral transmission are significantly lower with
S/D plasma when compared to FFP [10].
Congenital deficiency of factor five or parahemophilia is
an extremely rare disorder with an estimated prevalence of
1 in 1 million [11]. Less than 200 cases of inherited factor
five deficiency have been reported since its first descrip-
tion by Owren in 1947 in a woman with menorrhagia
[12]. Combined factor V and VIII deficiency has also been
described and probably occurs more commonly than fac-
tor V deficiency alone. It is an autosomal recessive trait
[1,2,4], manifests clinically only in patients who inherit
defective genes from both the parents. Other modes of
inheritance have been implicated in certain kindreds
[2,3]. In heterozygotes, the level of factor five in plasma is
approximately half of the normal and the carriers are eas-
ily identifiable by routine laboratory studies [4]. A recent
study detailing molecular analysis of factor V gene in
patients with severe factor V deficiency revealed 9 differ-
ent mutations [13]. These researchers felt that there was a
high level of allelic heterogeneity in these cases with a
large number of "private" mutations in FV-deficient fami-
lies. For this reason they recommend a full mutational
screening of FV gene in affected individuals for a complete
molecular diagnosis.
The clinical features are rather mild compared with hemo-
philia and the patients experience few bleeding problems
in daily life but experience bleeding complications follow-
ing dental extraction, severe trauma or surgery. The goal of
hematologic management in the perioperative period is to
maintain sufficient levels of clotting factors for a sufficient
period of time to prevent bleeding complications. Con-
ventional regimen for patients with congenital clotting
factor deficiency undergoing major elective surgery is to
bring patient's plasma level to 100% just prior to surgery,
maintain a level greater than 60% for 4 days and a level
greater than 40% for 4 days [14]. However, the safe
plasma factor V level for major surgery is thought to be
25% to 33% and there are case reports where elective sur-
gery has been successfully performed above that level. In
one of the reports bleeding occurred 54 and 78 hours fol-
lowing dental extraction and factor V levels at these times
were 24% and 18% of normal, respectively [5]. Hence, it
is important to maintain adequate levels of factor V in the
postoperative period. Recommended dosage of FFP
replenishment in these patients undergoing major surgery
is 20 ml/kg of body weight as loading dose over 3–4 h to
prevent the adverse effects of volume overload followed
by 10 ml/kg every 12–24 hours [9], as has been used by
us. This high dose regimen recommended for severe factor
V deficient individuals was deliberately chosen because
the exact level of factor V activity was not available to us.
This technical limitation forced us to 'err' on the side of
surgical safety as haemorrhage during the surgery for por-
tal hypertension could have been lethal.
The simultaneous occurrence of factor V deficiency with
EHPVO has not been described till date. We have not
encountered a single case of factor V deficiency in 808
cases of EHPVO we have operated on since 1976 [[6,7]
and unpublished data]. EHPVO is a relatively common
cause of portal hypertension in India, especially in the
younger age group [6,7]. Splenectomy and PLRS is an
effective treatment (secondary prophylaxis) for this condi-
tion and is successful in preventing variceal rebleeding in
almost 90% of cases [7]. This operation also takes care of
the large splenomegaly and associated hypersplenism. As
the liver function is normal in these patients, PLRS is not
associated with post shunt encephalopathy. PLRS is con-
sidered a major undertaking with a potential for signifi-
cant morbidity and mortality, and many prefer
endoscopic sclerotherapy (EST) for the control of esopha-
geal varices. These patients usually have multiple collat-
eral vessels in the lienorenal and gastrosplenic ligaments,
splenic attachments to the diaphragm and in the retroper-
itoneum around splenic and renal vessels. As mobiliza-
tion of the spleen and splenic vein may cause significant
hemorrhage, painstaking ligation of these collaterals dur-
ing splenectomy and meticulous dissection of often thin
walled, distended and friable splenic vein from pancreaticBMC Surgery 2006, 6:7 http://www.biomedcentral.com/1471-2482/6/7
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tail is required. However, in centers with substantial expe-
rience the complication rate is low; our own elective mor-
tality rate for PLRS is 0.7%, variceal rebleeding rate is 11%
and encephalopathy rate is zero [7]. Moreover, PLRS is a
one time procedure for EHPVO which treats the painfully
enlarged spleen, hypersplenism and portal hypertension
all at the same time. It eliminates the risk of variceal bleed-
ing immediately whereas EST takes an average of 8 sittings
over many months to obliterate varices [15]. The patient
remains at risk of rebleed until the varices are obliterated.
Also, following EST the portal system is not decompressed
and these patients are at 16% risk of variceal recurrence in
esophagus [15] and 11% develop new varices in stomach
[16], with consequent high rebleed rates, as had hap-
pened in our patient following EST. These patients are
also at risk of development of ectopic varices and bile duct
varices with portal biliopathy following EST. Hence there
is a strong case for decompressive shunt surgery in these
EHPVO patients particularly in Indian conditions where
access to tertiary medical care and safe blood banks is lim-
ited.
Conclusion
A patient with coagulation disorder is more likely to be at
risk of recurrent life threatening gastrointestinal bleeding
from portal hypertension and blood-borne viral diseases
and are consequently more likely to benefit from an effec-
tive portal decompressive procedure. Our experience with
this case suggests that this surgical procedure can be safely
undertaken in clotting factor deficient patients with non
cirrhotic portal hypertension if meticulous surgical
hemostasis is achieved at operation and the deficient fac-
tor is adequately replaced in the perioperative period until
wound healing has sufficiently progressed to prevent fur-
ther bleeding.
Abbreviations
APTT: activated partial thromboplastin time
EHPVO: extra-hepatic portal venous obstruction
EST: endoscopic sclerotherapy
FFP: fresh frozen plasma
PLRS: proximal lieno-renal shunt
PT: prothrombin time
TEG: thromboelastogram
UGI: upper gastrointestinal
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SPC  collated the information, searched literature and
wrote and revised the manuscript. SP assisted in literature
search, writing of the manuscript, editing the final script,
revising and doing the final submission. SG, RK, PS and
TKC assisted in providing a critical appraisal and review of
the manuscript. RK provided the main hematologic input.
References
1. Tsuda H, Mizuno Y, Hara T, Ohtsuki T, Ueda K, Matsuzaki K, Watan-
abe T: A case of congenital factor V deficiency combined with
multiple congenital anomalies: successful management of
palatoplasty.  Acta Haematol 1990, 83:49-52.
2. Seeler RA: Parahemophilia. Factor V deficiency.  Med Clin North
Am 1972, 56:119-25.
3. Melliger EJ, Duckert F: Major surgery in a subject with factor
Vdeficiency. Cholecystectomy in a parahaemophilic woman
and review of the literature.  Thromb Diath Haemorrh 1971,
25:438-46.
4. Brummel-Ziedins K, Orfeo T, Jenny NS, Everse SJ, Mann KG: Blood
Coagulation and Fibrinolysis.  In Wintrobe's Clinical Hematology
11th edition. Edited by: Greer JP, Rodgers GM, Foerster J, Paraskevas
F, Lukens JN, Glader B. Philadelphia: Lippincott Williams & Wilkins;
2004:677-774. 
5. Webster WP, Roberts HR, Penick GD: Hemostasis in Factor V
deficiency.  Am J Med Sci 1964, 248:194-202.
6. Sahni P, Pande GK, Nundy S: Extrahepatic portal vein obstruc-
tion.  Br J Surg 1990, 77:1201-2.
7. Prasad AS, Gupta S, Kohli V, Pande GK, Sahni P, Nundy S: Proximal
Splenorenal Shunts for Extrahepatic Portal VenousObstruc-
tion in Children.  Ann Surg 1994, 19:193-6.
8. Webb LJ, Sherlock S: The aetiology, presentation and natural
history of extra-hepatic portal venous obstruction.  Q J Med
1979, 48:627-39.
9. Yotsumoto G, Masuda H, Toyokawa K, Iguro Y, Kinjo T, Sakata R:
Off-pump coronary artery bypass grafting in a patient with
congenitalfactor V deficiency: report of a case.  Surg Today
2005, 35:142-4.
10. Doyle S, O'Brien P, Murphy K, Fleming C, O'Donnell J: Coagulation
factor content of solvent/detergent plasma compared with
fresh frozen plasma.  Blood Coagul Fibrinolysis 2003, 14:283-7.
11. Friedman KD, Rodgers GM: Inherited coagulation disorders.  In
Wintrobe's Clinical Hematology 11th edition. Edited by: Greer JP, Rodg-
ers GM, Foerster J, Paraskevas F, Lukens JN, Glader B. Philadelphia:
Lippincott Williams & Wilkins; 2004:1619-1668. 
12. Owren PA: Parahaemophilia. Haemorrhagic diathesis due to
absence of a previously unknown clotting factor.  Lancet 1947,
1:446.
13. Montefusco MC, Duga S, Asselta R, Malcovati M, Peyvandi F, Santago-
stino E, et al.:  Clinical and molecular characterization of 6
patients affected by severe deficiency of coagulation fac-
torV:broadening of the mutational spectrum of factorV gene
and in vitro analysisof the newly identified missense muta-
tions.  Blood 2003, 102:3210-3216.
14. Krieger JN, Hilgartner MW, Redo SF: Surgery in patients with
congenital disorders of blood coagulation.  Ann Surg 1977,
185:290-4.
15. Bhargava DK, Dwivedi M, Dasarathy S, Arora A: Endoscopic scle-
rotherapy for portal hypertension due to extrahepatic
obstruction: long-term follow-up.  Gastrointest Endosc 1989,
35:309-11.
16. Chawla YK, Dilawari JB, Ramesh GN, Kaur U, Mitra SK, Walia BN:
Sclerotherapy in extrahepatic portal venous obstruction.
Gut 1990, 31:213-6.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Surgery 2006, 6:7 http://www.biomedcentral.com/1471-2482/6/7
Page 5 of 5
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2482/6/7/prepub